Back to School: How biopharma can reboot drug development. Access exclusive analysis here
POZN gained $2.78 (28%) to $12.26 on news that it and partner AstraZeneca (LSE:AZN; AZN) will begin a Phase
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury